AJMC August 24, 2024
New research indicates that the heart benefits of semaglutide can extend to those with heart failure.
Weight loss drug semaglutide may help prevent heart attacks and other major adverse cardiac events (MACE) among people classfied as overweight who also have cardiovascular disease, regardless if they also have heart failure, according to new research published in The Lancet.1
In a recent analysis from the SELECT trial, researchers reported that semaglutide 2.4 mg (Wegovy; Novo Nordisk), a glucagon-like peptide 1 (GLP-1) receptor agonist approved for weight loss, significantly lowered the risk of MACE and heart failure in patients with atherosclerotic cardiovascular disease and overweight or obesity, regardless of heart failure presence or type. The overall study included more than 17,600 participants, with...
Today's Sponsors
Today's Sponsor